ArticleCommunications medicine2022

Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer.

Lianxi Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.